A First-in-Human, Randomised, Double Blind, Placebo Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2017
At a glance
- Drugs AJM 347 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors EA Pharma
- 23 Aug 2017 Status changed from not yet recruiting to recruiting.
- 17 May 2017 Planned End Date changed from 1 Nov 2018 to 1 Mar 2018.
- 17 May 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Aug 2018.